Viruses 2011, 3(4), 347-378; doi:10.3390/v3040347

Clinical Management of HIV Drug Resistance

HIV Drug Resistance Program, NCI, NIH, Building 10 Rm 5A06, Bethesda, MD 20892, USA
* Author to whom correspondence should be addressed.
Received: 9 March 2011; Accepted: 30 March 2011 / Published: 14 April 2011
(This article belongs to the Special Issue HIV Drug Resistance)
PDF Full-text Download PDF Full-Text [687 KB, uploaded 14 April 2011 16:11 CEST]
Abstract: Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy.
Keywords: HIV; drug resistance testing; clinical management

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Cortez, K.J.; Maldarelli, F. Clinical Management of HIV Drug Resistance. Viruses 2011, 3, 347-378.

AMA Style

Cortez KJ, Maldarelli F. Clinical Management of HIV Drug Resistance. Viruses. 2011; 3(4):347-378.

Chicago/Turabian Style

Cortez, Karoll J.; Maldarelli, Frank. 2011. "Clinical Management of HIV Drug Resistance." Viruses 3, no. 4: 347-378.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert